Vir Pharma Signs Supply Agreement with Canadian Cannabis Firm

Vir Pharma has signed with Sundial for a three year agreement to receive cannabis oil from the Canadian marijuana company for its oral formulation for chronic pain.

A Canadian cannabis producer is stepping into the Australian cannabis landscape through a supply agreement for medical cannabis oil.

New South Wales-based Vir Pharma Holdings has signed on with Sundial Growers (NASDAQ:SNDL) for a three year agreement to receive cannabis oil from the Canadian marijuana company for its oral formulation for chronic pain.

The drug is to be distributed for commercial and research use across Australia and offers an alternative to opioid-based pain treatments, Sundial said.

In an emailed statement to the Investing News Network (INN), Brian Harriman, chief operating officer at Sundial, said the two firms are well aligned for a partnership because of their mutual focus on the therapeutic effects of marijuana.

“Vir Pharma is a company with similar strategic interest in medical cannabis, and we feel our collective capabilities will bring synergistic benefits to both companies,” Harriman told INN.

Since the news was announced last Thursday (January 9), Sundial’s share price has been up just over 5 percent.

Sundial said it expects to send the first shipments of its cannabis oil to Vir before the end of April 2020.

Though Sundial is currently focused on its expansion into Australia, the executive added that the company plans to use information from its agreement with Vir Pharma for future partnerships with other international firms moving forward.

“This is a significant announcement for Sundial and our Heal (medical) business as it will lead to our first global exports and entry into Australian markets,” said Harriman in a press release.

Vir Pharma, a licensed medical cannabis importer and manufacturer in Australia, is currently developing Virabis, a pain treatment drug that’s up for approval from the Therapeutic Goods Administration (TGA), the country’s regulator of medicinal products.

Vir plans on leveraging Sundial’s cultivation expertise with its own experience in medical cannabis product production to further develop medical marijuana-based treatments.

Joel Hardy, CEO at Vir Pharma, said that along with the creation of the cannabis drug, the agreement will allow the firm to start a clinical development program.

Sundial joins the likes of MediPharm Labs (TSX:LABS,OTCQX:MEDIF), another Canadian marijuana company, in branching out into the Australian cannabis market recently.

In June last year, MediPharm announced its first shipments of medical cannabis concentrate to Western Australian cannabis pharmaceutical company AusCann Group Holdings (ASX:AC8).

Aleafia Health (TSX:ALEF,OTCQX:ALEAF) has also been supplying the Australian cannabis space with its branded medical cannabis oils through an agreement with its partner CannaPacific.

Don’t forget to follow us @INN_Australia for real-time news updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: MediPharm Labs is a client of the Investing News Network. This article is not paid-for content

AU$4 Billion Galaxy/Orocobre Merger to Create Top 5 Lithium Company

Australia’s Orocobre (TSX:ORL,ASX:ORE) and Galaxy Resources (ASX:GXY,OTC Pink:GALXF) agreed this week to join forces in a AU$4 billion “merger of equals.” The deal comes as demand for lithium for electric vehicle (EV) batteries continues to pick up pace.

Once the merger is complete, the new company will become a top five lithium chemicals company globally — and top three outside of China — with production capacity of around 40,000 tonnes of lithium carbonate equivalent per year.

“The merged entity’s growth opportunities in both brine and hard rock position it uniquely to take advantage of expected rising EV demand for lithium,” Galaxy Chairman Martin Rowley said.

Keep reading... Show less

IIROC Trading Halt – TMRR

The following issues have been halted by IIROC:

Company: Tempus Resources Ltd.

Keep reading... Show less

Cleantech Investing in Australia

Climate change is a looming issue for Australians, with 82 percent concerned about bushfires and 81 percent worried that drought or flooding will affect crop production and food supply.

This is where conscious investors look to the cleantech sector, which covers everything from renewable energy to low-emission technologies to water technology to battery storage and more.

What should investors know about cleantech in Australia before they jump in? Read on for a look at key factors, including market size, the industries encompassed by cleantech and big players to watch.

Keep reading... Show less

Galaxy Resources Limited Announcement

Galaxy Resources Limited (ASX: GXY) ( Company ) advises that the following announcement has been made to the Australian Securities Exchange which appears on the Company’s platform (ASX):

  • Becoming a substantial holder

The announcement can be viewed at:
https://www2.asx.com.au/markets/trade-our-cash-market/announcements.gxy

Keep reading... Show less

Hastings Technology Metals Ltd Signs Major Offtake Contract with thyssenkrupp

Perth, Australia (ABN Newswire) – Australia’s next rare earths producer Hastings Technology Metals Limited (ASX:HAS) is pleased to announce that it has executed a binding offtake contract with thyssenkrupp Materials Trading GmbH (TK), for high-grade mixed rare earth carbonate (MREC) from the Company’s Yangibana Rare Earths Project (Yangibana) in the Gascoyne region of Western Australia.

Highlights

– Hastings announces signing of a major offtake contract for the supply of its high grade product from its Yangibana Rare Earths Project in Western Australia to thyssenkrupp Materials Trading GmbH.

Keep reading... Show less

Top News

Related News